{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:51:14Z","timestamp":1761709874277,"version":"3.41.2"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Vulvar cancer is the fourth most common gynecologic cancer, and prognosis is poor in advanced vulvar cancer patients. Treatment for advanced vulvar cancer has not been satisfactory. In this report, we firstly report a FIGO IVB vulva verrucous carcinoma patient who obtained good prognosis after systemic treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A patient was admitted to hospital due to her vulvar lesion persistent for past 14 years. The vulvar mass has widely invaded urethra, part of anus, the lower third of the vagina, bilateral superior and inferior branches of pubis, and bilateral internal and external muscles of obturator. Multiple metastatic lymph nodes were also found in the pelvic cavity. The histopathological studies confirmed vulvar verrucous carcinoma with a PD-L1 overexpression. After six courses of neoadjuvant chemotherapy and pembrolizumab, the patient\u00a0underwent radical vulvectomy and achieved optimal cytoreduction. Postoperative pathology found no residual tumor. The patient then received one course of postoperative chemotherapy and pembrolizumab, underwent radiation therapy, and was disease free after 6 months follow-up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our individualized treatment strategy is successful. Pembrolizumab is safe and effective in the treatment of advanced vulvar verrucous carcinoma with PD-L1 overexpression.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.598594","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T08:52:13Z","timestamp":1622191933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Pembrolizumab in FIGO IVB Verrucous Carcinoma of the Vulva: A Case Report"],"prefix":"10.3389","volume":"11","author":[{"given":"Yuhan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongchun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bingzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongqiu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer Statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S68979","article-title":"Vulvar Cancer: Epidemiology, Clinical Presentation, and Management Options","volume":"7","author":"Alkatout","year":"2015","journal-title":"Int J Womens Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0009","article-title":"Surgical Management of Vulvar Cancer","volume":"15","author":"Dellinger","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.12.007","article-title":"Locally Advanced Vulva Cancer: A Single Centre Review of Anovulvectomy and a Systematic Review of Surgical, Chemotherapy and Radiotherapy Alternatives. Is an International Collaborative RCT Destined for the \u201cToo Difficult to do\u201d Box","volume":"144","author":"O\u2019Donnell","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S105862","article-title":"Pd-L1 Expression in Human Cancers and its Association With Clinical Outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"OncoTargets Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000491090","article-title":"Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature","volume":"84","author":"Shields","year":"2019","journal-title":"Gynecol Obstetr Invest"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0000000000000164","article-title":"Verrucous Carcinoma of the Vulva: A 20 Year Retrospective Study and Literature Review","volume":"20","author":"Liu","year":"2016","journal-title":"J Low Genit Tract Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"932712","DOI":"10.1155\/2013\/932712","article-title":"Verrucous Carcinoma of the Vulva: A Case Report","volume":"2013","author":"Boutas","year":"2013","journal-title":"Case Rep Obstetr Gynecol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.914367","article-title":"Verrucous Carcinoma of the Vulva: A Case Report and Literature Review","volume":"20","author":"Zhang","year":"2019","journal-title":"Am J Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(97)80315-5","article-title":"Human Papillomavirus-Associated Tumors of the Skin and Mucosa","volume":"36","author":"Majewski","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1988.tb06617.x","article-title":"Verrucous Carcinoma of the Vulva Containing Human Papillomavirus-11. Case Report","volume":"95","author":"Crowther","year":"1988","journal-title":"Br J Obstetr Gynaecol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20174929","article-title":"Verrucous Carcinoma of the Vulva: Diagnosis and Treatment","volume":"92","author":"Campaner","year":"2017","journal-title":"Anais Bras Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00270-1","article-title":"A Case Report of Multicentric Verrucous Carcinoma of the Female Genital Tract","volume":"90","author":"Yorganci","year":"2003","journal-title":"Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.6004\/jnccn.2017.0008","article-title":"Vulvar Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Koh","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"B15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/1097-0142(196601)19:1<26::AID-CNCR2820190103>3.0.CO;2-L","article-title":"Verrucous Carcinoma. Clinical and Pathologic Study of 105 Cases Involving Oral Cavity, Larynx and Genitalia","volume":"19","author":"Kraus","year":"1966","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1148\/86.1.108","article-title":"Anaplastic Transformation in Verrucous Carcinoma of the Oral Cavity After Radiation Therapy","volume":"86","author":"Perez","year":"1966","journal-title":"Radiology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in Ovarian Cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced and Unresectable or Metastatic Urothelial Cancer (KEYNOTE-052): A Multicentre, Single-Arm, Phase 2 Study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.598594\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T08:52:15Z","timestamp":1622191935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.598594\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":19,"alternative-id":["10.3389\/fonc.2021.598594"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.598594","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"article-number":"598594"}}